ChrysCapital-backed Eris Lifesciences may get EY partner V Krishnakumar on board

Over the course of the next few months, Krishnakumar is likely to join the pharma company as an Executive Director overseeing operations

India will be known for pharma; 4-5 cos can turn multibaggers: Pritam Deuskar

Pharma companies that bottomed out in 2019 with all data integrity issues getting solved are now totally thriving with countries that were spending less % of GDP on it are now doing it and storing drugs.

DAILY VOICE | Geopolitics & appreciating dollar can turn the tide away from bulls: Satish Kumar

"In the current scenario, we can never say that the worst is over in the equity markets, any negative news on the geopolitical level will take it down. I am not worried about the COVID-19 situation though."

D-Street Talk podcast | Pharma earnings to double in 4-5 years says fund manager with AUM of over Rs 20,000 cr

Bhan is of the view that the improvement in the pharma sector in the last 4-5 months is also the function of improvement in the fundamentals of the companies.

India may increase customs duty on import of active pharma ingredients by 10-15%: Report

At present, 70 percent of India’s API requirement is sourced from China, while for antibiotics in particular, the dependence is over 90 percent

Coronavirus vaccine | Pfizer’s US deal sets price cap for other manufacturers: Report

The Pfizer deal at roughly $2 billion deal translates into per dose price of $20. Competitors will, therefore, be forced to offer their coronavirus vaccine in a similar price range

Centre set to make QR codes a must for medicine packs: Report

A committee has been set up under the health secretary and a report is expected in the next 21 days.

China's Fosun pulls back from healthcare deals worth $300 million in India: Report

As per reports, Fosun had made a formal proposal to purchase stake in two companies.

Novo Nordisk joins hands with AMR Action Fund to fight antimicrobial resistance

The fund aims to bring 2-4 new antibiotics to market this decade that will save patients' lives.

The wrong way to go about curbing imports from China

Let the axe first fall on low quality non-essential imports like cheap toys. Then have a graded strategy of domestic manufacturing of items according to how important they are and what scope there is for value addition

Contract research firm Anthem Biosciences looks to sell minority stake in deal valuing firm at $1 billion

“Anthem Biosciences is looking to tap investors, primarily private equity funds & sell a 10 percent stake in the firm and raise around $100 million. If plans fructify, this would value the firm at a billion dollars," a source said.

India's auto and pharma sectors not ready to wean off China

Like many countries, India relies on China for products such as electronic components and drug ingredients because it cannot make them or source them elsewhere as cheaply, company and industry figures say.

'Pharma looks attractive, but auto sector may turn out to be the dark horse'

The sector to watch still remains pharma. The valuation is still way off the valuations the sector governed even around 5 years back, thus creating an upward space.

Cipla to acquire 21.85% stake in GoApptiv

In the first stage, subscription of 15,392 compulsorily convertible preference shares and purchase of 6,927 equity shares is expected to be closed within 30 days from the execution date, subject to certain conditions precedent.

Pharma stocks end 5-year of bear phase; Lupin, Aurobindo among top 5 buys

Experts feel that the current environment is more conducive for the Pharma sector and the rally is likely to continue in some of the names.

COVID-19 impact | Pharma, medical health equipment companies may drive demand for commercial spaces

Some experts feel commercial lease rentals may come under pressure in a few locations and may witness a decline of at least 20 percent.

Which companies could gain as global supply chains shift from China – Part 2

Carlyle and former Mylan top executive in talks to buy Ra Chem Pharma from Micro Labs

The Carlyle-Hari Babu consortium is in advanced stages of negotiations to buy out Hyderabad-based API ( active pharmaceutical ingredients) maker Ra Chem Pharma from majority stakeholder and parent Micro Labs.

'More pain left, bear markets have lasted for a minimum of 18 months'

Investors should, therefore, patiently wait and get into sectoral leaders to prevent wealth erosion in the coming months, says Umesh Mehta.

Dr Reddy's launches generic lipid-regulating tablets in US

The company's tablets are available in 54 mg dose in bottle count size of 90, and 160 mg dose in bottle count sizes of 90 and 500

Aurobindo Pharma gets VAI classification from USFDA for Hyderabad unit

Aurobindo Pharma on Tuesday said the US health regulator has decided that the inspection classification of company's injectable formulation manufacturing facility at Hyderabad is voluntary action indicated (VAI).

Strides receives USFDA approval for Flucytosine Capsules

The product is a generic version of Ancobon Capsules, 250 mg and 500 mg, of Bausch Health US, LLC, the Bengaluru- headquartered pharmaceutical company said in a statement.

Pharma sector sits pretty amid market turmoil; 5 stocks that you can buy

The panic created by COVID-19 has taken a heavy toll on most sectors but pharma companies seem to have withstood the carnage, with some stocks delivering healthy returns during this period.

Sensex jumps over 2,400 points; 4 factors which fuelled the rally

Sectorally, the action was seen in healthcare, IT, Realty, Bankex, Telecom, and Auto stocks which are trading with gains of over 4 percent each.

Malaria drugs’ promise for coronavirus spurs hope, shortages

Chloroquine and a similar drug, hydroxychloroquine, showed encouraging signs in small, early tests against the coronavirus. But the drugs have major side effects, one reason scientists don’t want to give them without evidence of their value, even in this emergency.